Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ceftazidime + avibactam PK and safety study in neonates and infants with suspected or confirmed Gram-negative infection
2018-002800-16Phase 2Completed
- Sponsor
- Pfizer
- Start
- Oct 2019
- Modality
- Reversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules, Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of ceftazidime and avibactam in Gram-negative bacterial infection and bacterial disease (2 arms), sponsored by Pfizer. Started Oct 2019; status: completed.
02
Drugs
ceftazidimeavibactam
03
Conditions
Gram-negative bacterial infectionbacterial disease
Beyond the preview
Go deeper on 2018-002800-16.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2018-002800-16.